Compugen (CGEN, Financial) recently experienced a notable stock price surge of 5.49%, reaching $1.73 per share. The trading volume was approximately 288,117 shares, with a turnover rate of 0.32% and a price fluctuation of 6.56%.
The latest financial report indicates Compugen's revenue at $6.70 million, with a net loss of $2.12 million, and earnings per share at -$0.02. The gross profit margin stands at $5.15 million, and the price-to-earnings ratio is -17.20. Notably, all three rating agencies covering Compugen have recommended buying the stock, with none suggesting holding or selling.
Amidst the broader biotechnology sector, which experienced a decline of 0.40%, several stocks saw significant activity. Notable performers included 60 Degrees Pharmaceuticals Inc and Lixte Biotechnology Holdings Inc, while Sonnet Biotherapeutics Holdings, Inc. and Elevai Labs, Inc. demonstrated high turnover rates and volatility.
Compugen is a clinical-stage company focused on drug discovery and development using predictive computational techniques. The company targets new drug pathways for cancer immunotherapy, with an active pipeline including clinical-stage projects like COM701 and COM902.
